Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL4667472 | 0.96 | PAX8 (0.44) | PAX8HTR6TSHRRAB9AGSK3B | |
| Formic Acid SCHEMBL4666146 | 0.95 | HTR6 (0.38) | PAX8HTR6RAB9AGSK3BKDM4E | |
| Formic Acid SCHEMBL4664367 | 0.93 | ABL1 (0.41) | HTR6HRH3GSK3BACP1MAPT | |
| Formic Acid SCHEMBL4665737 | 0.93 | LMNA (0.42) | HTR6GSK3BACP1KITLMNA | |
| Formic Acid SCHEMBL4664334 | 0.91 | RAB9A (0.39) | PAX8HTR6RAB9AGSK3BKDM4E | |
| Formic Acid SCHEMBL4665807 | 0.89 | HTR6 (0.44) | HTR6GSK3BMAPTKITLMNA | |
| Formic Acid SCHEMBL4666206 | 0.88 | ABL1 (0.41) | HTR6GSK3BMAPTKIT | |
| Formic Acid SCHEMBL4666208 | 0.87 | HTR6 (0.46) | HTR6KDM4EGAAMAPT | |
| Formic Acid SCHEMBL4667364 | 0.86 | HTR6 (0.41) | HTR6TSHRACP1 | |
| Formic Acid SCHEMBL4666157 | 0.86 | HTR6 (0.41) | HTR6RAB9AACP1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | PAX8 3610/4885HTR6 826/4885TSHR 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.